Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy

Journal of Pediatrics

Volumn 145, Issue 3, 2004, Pages 346-352

  Ware, Russell E ^a,b   Zimmerman, Sherri A ^a   Sylvestre, Pamela B ^a   Mortier, Nicole A ^a   Davis, Jacqueline S ^a   Treem, William R ^a   Schultz, William H ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Absolute neutrophil count; ANC; Fetal hemoglobin; HbF; Maximum tolerated dose; MTD; SCA; Sickle cell anemia; WBC; White blood cell

Indexed keywords

FERRITIN; HEMOGLOBIN F; HYDROXYUREA; IRON;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEMIPLEGIA; HEMOGLOBIN DETERMINATION; HISTOLOGY; HUMAN; IRON OVERLOAD; LIVER BIOPSY; MALE; MEAN CORPUSCULAR VOLUME; NEUROLOGIC DISEASE; NEUTROPENIA; PHLEBOTOMY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SICKLE CELL ANEMIA; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CEREBROVASCULAR ACCIDENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYUREA; INFANT; IRON OVERLOAD; MALE; PHLEBOTOMY; PROSPECTIVE STUDIES; RECURRENCE;

EID: 4444309490     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2004.04.058     Document Type: Article

References (40)

1. Hughes J.G., Diggs L.W., Gillespie C.E. The involvement of the nervous system in sickle cell anemia. J Pediatr. 17:1940;166-184
2. Stockman J.A., Nigro M.A., Mishkin M.M., Oski F.A. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 287:1972;846-849
3. Baird R.L., Weiss D.L., Ferguson A.D., French J.H., Scott R.B. Studies in sickle cell anemia, XXI: clinico-pathological aspects of neurological manifestations. Pediatrics. 34:1964;92-100
4. Adams R.J., Nichols F.T., McKie V., McKie K., Milner P., Gammal T.E. Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology. 38:1988;1012-1017
5. Powars D., Wilson B., Imbus C., Pegelow C., Allen J. The natural history of stroke in sickle cell disease. Am J Med. 65:1978;461-471
6. Moohr J.W., Wilson H., Pang E.J.-M. Strokes and their management in sickle cell disease. Fried W. Comparative clinical aspects of sickle cell disease. 1982;101-111 Elsevier North Holland, Amsterdam
7. Powars D., Chan L.S., Schroeder W.A. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 27:1990;360-376
8. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol. 28:1991;213-219
9. Balkaran B., Char G., Morris J.S., Thomas T.W., Serjeant B.E., Serjeant G.R. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 120:1992;360-366
10. Ohene-Frempong K., Weiner S.J., Sleeper L.A., Miller S.T., Embury S., Moohr J.W., et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 91:1998;288-294
11. AAP Newborn Screening Taskforce. Serving the family from birth to the medical home: newborn screening: a blueprint for the future. Pediatrics. 106:(suppl):2000;383-427
12. Powars D., Imbus C. Cerebral vascular accidents in sickle cell anemia. Texas Reports Biol Med. 40:1980;293-304
13. Russell M.O., Goldberg H.I., Hodson A., Kim H.C., Halus J., Reivich M., et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 63:1984;162-169
14. Lusher J.M., Haghighat H., Khalifa A.S. A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol. 1:1976;265-273
15. Russell M.O., Goldberg H.I., Reis L., Friedman S., Slater R., Reivich M., et al. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease. J Pediatr. 88:1976;382-387
16. Pegelow C.H., Adams R.J., McKie V., Abboud M., Berman B., Miller S.T., et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 126:1995;896-899
17. Scothorn D.J., Price C., Schwartz D., Terrill C., Buchanan G.R., Shurney W., et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 140:2002;348-354
18. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J. The risk of transfusion-transmitted viral infections: the Retrovirus Epidemiology Donor Study. N Engl J Med. 334:1996;1685-1690
19. Rosse W.F., Gallagher D., Kinney T.R., Castro O., Dosik H., Moohr J., et al. Transfusion and alloimmunization in sickle cell disease. Blood. 76:1990;1431-1437
20. Vichinsky E.P., Luban N.L., Wright E., Olivieri N., Driscoll C., Pegelow C.H., et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 41:2001;1086-1092
21. Castellino S.M., Combs M.R., Zimmerman S.A., Issitt P.D., Ware R.E. Erythrocyte autoantibodies in pediatric patients receiving transfusion therapy: frequency, characteristics, and significance. Br J Haematol. 104:1999;189-194
22. Ballas S.K. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 38:(suppl):2001;30-36
23. Files B., Brambilla D., Kutlar A., Miller S., Vichinsky E., Wang W., et al. Longitudinal changes in ferritin during chronic transfusion: a report from the stroke prevention trial in sickle cell anemia (STOP). J Pediatr Hematol/Oncol. 24:2002;284-290
24. Ware R.E., Steinberg M.H., Kinney T.R. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol. 50:1995;140-143
25. Ware R.E., Zimmerman S.A., Schultz W.H. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 94:1999;3022-3026
26. Charache S., Dover G.J., Moore R.D., Eckert S., Ballas S.K., Koshy M., et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell disease. Blood. 79:1992;2555-2565
27. Kinney T.R., Helms R.W., O'Branski E.E., Ohene-Frempong K., Wang W., Daeschner C., et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a Phase I/II trial. Blood. 94:1999;1550-1554
28. Adams D.M., Schultz W.H., Ware R.E., Kinney T.R. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol/Oncol. 18:1996;46-50
29. Wilimas J., Goff J.R., Anderson H.R. Jr., Langston J.W., Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr. 96:1980;205-208
30. Wang W.C., Kovnar E.H., Tonkin I.L., Mulhern R.K., Langston J.W., Day S.W., et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 118:1991;377-382
31. Lane P.A., Buchanan G.R., Ware R.E. Variable approaches to therapeutic options for children with sickle cell disease (SCD): a practice survey of the American Society of Pediatric Hematology/Oncology (ASPH/O). Blood. 98:2001;784a
32. Olivieri N.F. Progression of iron overload in sickle cell disease. Semin Hematol. 38:(suppl):2001;57-62
33. Treadwell M.J., Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin Hematol. 38:(suppl):2001;77-84
34. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., et al. Effect of hydroxyurea on frequency of painful crisis in sickle cell anemia. N Engl J Med. 332:1995;1317-1322
35. Bunn H.F. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 337:1997;762-769
36. Vichinsky E.P., Lubin B.H. A cautionary note regarding hydroxyurea in sickle cell disease. Blood. 83:1994;1124-1128
37. Scott J.P., Hillery C.A., Brown E.R., Misiewicz V., Labotka R.J. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 128:1996;820-828
38. de Montalembert M., Belloy M., Bernaudin F., Gouraud F., Capdeville R., Mardini R., et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease: the French Study Group on Sickle Cell Disease. J Pediatr Hematol/Oncol. 19:1997;313-318
39. Zimmerman S.A., Schultz W.H., Davis J.S., Pickens C.V., Mortier N.A., Howard T.A., et al. Sustained long-term hematological efficacy of hydroxyurea therapy for children with sickle cell disease. Blood. 103:2004;2039-2045
40. Angelucci E., Muretto P., Lucarelli G., Ripalti M., Baronciani D., Erer B., et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood. 90:1997;994-998